FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3188787536> ?p ?o ?g. }

• W3188787536 endingPage "175628482110323" @default.
• W3188787536 startingPage "175628482110323" @default.
• W3188787536 abstract "Two studies demonstrated the efficacy and safety of naldemedine in adult patients with chronic non-cancer pain and opioid-induced constipation (OIC). However, no studies have compared the efficacy of peripherally acting µ-opioid receptor antagonists in patients with adequate and inadequate responses to prior OIC therapy with laxatives. This post hoc analysis of integrated data from the two previous studies compared the efficacy of naldemedine in patients who were unsuccessfully treated with laxatives [poor laxative responders (PLRs)] with those who either did not receive laxatives >30 days prior to screening or those who only received rescue laxative at or after screening (non-PLRs).Patients with OIC were randomized to once-daily treatment with naldemedine 0.2 mg or placebo. The primary efficacy endpoint was the proportion of responders [⩾3 spontaneous bowel movements (SBMs)/week and an increase from baseline of ⩾1 SBM/week for ⩾9 weeks of the 12-week treatment period and ⩾3 weeks of the final 4 weeks of the 12-week treatment period]. Additional endpoints included change in SBM frequency, change in frequency of SBMs without straining, proportion of complete SBM (CSBM) responders, change in CSBM frequency, and time to first SBM. Treatment-emergent adverse events (TEAEs) were assessed.The analysis included 538 (317 PLRs, 221 non-PLRs) and 537 (311 PLRs, 226 non-PLRs) patients in the naldemedine and placebo arms, respectively. There were significantly more responders in the naldemedine PLR (46.4%; p < 0.0001) and non-PLR (54.3%; p = 0.0009) subgroups versus the placebo groups (30.2% and 38.9%, respectively). In both the PLR and non-PLR subgroups, naldemedine treatment was superior to placebo on all additional endpoints. Overall incidence of TEAEs in the PLR subgroups treated with naldemedine or placebo was similar.This integrated analysis further supports the efficacy and tolerability of naldemedine in the treatment of OIC and demonstrates a consistent effect in both PLR and non-PLR subgroups.[ClinicalTrials.gov identifier: NCT01965158 and NCT01993940]." @default.
• W3188787536 created "2021-08-16" @default.
• W3188787536 creator A5021286381 @default.
• W3188787536 creator A5029752566 @default.
• W3188787536 creator A5049717177 @default.
• W3188787536 creator A5050602462 @default.
• W3188787536 creator A5058714238 @default.
• W3188787536 creator A5072458770 @default.
• W3188787536 creator A5086218839 @default.
• W3188787536 date "2021-01-01" @default.
• W3188787536 modified "2023-10-17" @default.
• W3188787536 title "Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives" @default.
• W3188787536 cites W1527482428 @default.
• W3188787536 cites W1576185322 @default.
• W3188787536 cites W1996075855 @default.
• W3188787536 cites W2040109649 @default.
• W3188787536 cites W2093685229 @default.
• W3188787536 cites W2097538787 @default.
• W3188787536 cites W2122946021 @default.
• W3188787536 cites W2143221646 @default.
• W3188787536 cites W2147808981 @default.
• W3188787536 cites W2176756126 @default.
• W3188787536 cites W2271853934 @default.
• W3188787536 cites W2278577905 @default.
• W3188787536 cites W2280428952 @default.
• W3188787536 cites W2333283069 @default.
• W3188787536 cites W2617664403 @default.
• W3188787536 cites W2758210674 @default.
• W3188787536 cites W2764073884 @default.
• W3188787536 cites W2782215515 @default.
• W3188787536 cites W2792218458 @default.
• W3188787536 cites W2897189621 @default.
• W3188787536 cites W2905357805 @default.
• W3188787536 cites W2952622458 @default.
• W3188787536 cites W3044279306 @default.
• W3188787536 cites W4211073917 @default.
• W3188787536 doi "https://doi.org/10.1177/17562848211032320" @default.
• W3188787536 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8326612" @default.
• W3188787536 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34377150" @default.
• W3188787536 hasPublicationYear "2021" @default.
• W3188787536 type Work @default.
• W3188787536 sameAs 3188787536 @default.
• W3188787536 citedByCount "2" @default.
• W3188787536 countsByYear W31887875362023 @default.
• W3188787536 crossrefType "journal-article" @default.
• W3188787536 hasAuthorship W3188787536A5021286381 @default.
• W3188787536 hasAuthorship W3188787536A5029752566 @default.
• W3188787536 hasAuthorship W3188787536A5049717177 @default.
• W3188787536 hasAuthorship W3188787536A5050602462 @default.
• W3188787536 hasAuthorship W3188787536A5058714238 @default.
• W3188787536 hasAuthorship W3188787536A5072458770 @default.
• W3188787536 hasAuthorship W3188787536A5086218839 @default.
• W3188787536 hasBestOaLocation W31887875362 @default.
• W3188787536 hasConcept C108797546 @default.
• W3188787536 hasConcept C121608353 @default.
• W3188787536 hasConcept C126322002 @default.
• W3188787536 hasConcept C142724271 @default.
• W3188787536 hasConcept C168563851 @default.
• W3188787536 hasConcept C197934379 @default.
• W3188787536 hasConcept C203092338 @default.
• W3188787536 hasConcept C204787440 @default.
• W3188787536 hasConcept C27081682 @default.
• W3188787536 hasConcept C2780661987 @default.
• W3188787536 hasConcept C2780955771 @default.
• W3188787536 hasConcept C2781112942 @default.
• W3188787536 hasConcept C42219234 @default.
• W3188787536 hasConcept C526805850 @default.
• W3188787536 hasConcept C71924100 @default.
• W3188787536 hasConcept C90924648 @default.
• W3188787536 hasConceptScore W3188787536C108797546 @default.
• W3188787536 hasConceptScore W3188787536C121608353 @default.
• W3188787536 hasConceptScore W3188787536C126322002 @default.
• W3188787536 hasConceptScore W3188787536C142724271 @default.
• W3188787536 hasConceptScore W3188787536C168563851 @default.
• W3188787536 hasConceptScore W3188787536C197934379 @default.
• W3188787536 hasConceptScore W3188787536C203092338 @default.
• W3188787536 hasConceptScore W3188787536C204787440 @default.
• W3188787536 hasConceptScore W3188787536C27081682 @default.
• W3188787536 hasConceptScore W3188787536C2780661987 @default.
• W3188787536 hasConceptScore W3188787536C2780955771 @default.
• W3188787536 hasConceptScore W3188787536C2781112942 @default.
• W3188787536 hasConceptScore W3188787536C42219234 @default.
• W3188787536 hasConceptScore W3188787536C526805850 @default.
• W3188787536 hasConceptScore W3188787536C71924100 @default.
• W3188787536 hasConceptScore W3188787536C90924648 @default.
• W3188787536 hasLocation W31887875361 @default.
• W3188787536 hasLocation W31887875362 @default.
• W3188787536 hasLocation W31887875363 @default.
• W3188787536 hasLocation W31887875364 @default.
• W3188787536 hasLocation W31887875365 @default.
• W3188787536 hasLocation W31887875366 @default.
• W3188787536 hasOpenAccess W3188787536 @default.
• W3188787536 hasPrimaryLocation W31887875361 @default.
• W3188787536 hasRelatedWork W2027243150 @default.
• W3188787536 hasRelatedWork W2072800071 @default.
• W3188787536 hasRelatedWork W2076385877 @default.
• W3188787536 hasRelatedWork W2090740252 @default.
• W3188787536 hasRelatedWork W2147976256 @default.

• next